OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Seidman Discusses Less Lymph Node Surgery

July 11th 2013

Andrew D. Seidman, MD, from Weill Cornell Cancer Center and Memorial Sloan-Kettering Cancer Center, discusses less surgery for patients with breast cancer.

Dr. Gogineni Comments on Oncology Drug Shortages

July 11th 2013

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Dr. Pardee on CPI-613 in Hematologic Malignancies

July 10th 2013

Timothy S. Pardee, MD, describes a phase I trial looking at the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Dr. Vogelzang on Two Analyses of the ALSYMPCA Trial

July 10th 2013

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial.

Electra D. Paskett, PhD, on Cervical Cancer Screening

July 9th 2013

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses the use of vinegar as a cervical cancer screening tool in the U.S.

Dr. Bruce Roth on Curing Cancer With Immunotherapies

July 9th 2013

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the optimism for a cure with immunotherapies.

Dr. Garcia on a Trial Analyzing the PARP Inhibitor Veliparib

July 8th 2013

Agustin A. Garcia, MD, from the Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.

Dr. Schuchter Discusses the Treatment of Melanoma

July 3rd 2013

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.

Dr. Aghajanian on PARP Inhibitors for Ovarian Cancer

July 3rd 2013

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the treatment of ovarian cancer with PARP inhibitors.

Dr. Parsa on a Trial Analyzing G-200 for Glioblastoma

July 2nd 2013

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.

Dr. Brentjens on Treatment With CAR-Modified T Cells

July 1st 2013

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of B-cell malignancies with chimeric antigen receptor(CAR)â€“modified T cells.

Dr. Gandara on the Heat Shock Protein 90 Inhibitor Ganetespib

July 1st 2013

David R. Gandara, MD, from UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.

Dr. Seidman on Personalized and Precision Medicine

June 28th 2013

Andrew D. Seidman, MD, from the Memorial Sloan-Kettering Cancer Center, describes his excitement over the genetic advances made in the treatment of patients with cancer.

Dr. Partridge on Dana-Farber's Adult Survivorship Program

June 28th 2013

Ann H. Partridge, MD, MPH, from Dana-Farber Cancer Institute and Harvard Medical School, gives an overview of the Adult Survivorship Program.

Dr. Schilsky on the Impact of Sequestration on the FDA

June 27th 2013

Richard L. Schilsky, MD, from the University of Chicago Comprehensive Cancer Center, discusses sequestration and the effect on the FDA.

Dr. Gulley on the Adverse Event Profile for PROSTVAC

June 27th 2013

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute (NCI), gives an overview of the adverse event profile for PROSTVAC.

Julian Adams on the IPI-145 Mechanism of Action

June 26th 2013

Julian Adams, PhD, from Infinity Pharmaceuticals, describes the mechanism of action for the experimental PI3 kinase delta/gamma inhibitor IPI-145 in hematologic malignancies.

Dr. Tendler on Breakthrough Designation for Ibrutinib

June 26th 2013

Craig L. Tendler, MD, Vice President, Late Development and Global Medical Affairs for Oncology, Janssen Oncology, discusses the importance of ibrutinib's Breakthrough Therapy Designation.

Dr. Mitchell on a Subgroup Analysis of the VELOUR Trial

June 26th 2013

Edith Mitchell, MD, FACP, from Thomas Jefferson University, gives an overview of the North American subgroup analysis of the VELOUR trial.

Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer

June 25th 2013

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, discusses the background and results of the S0221 trial in breast cancer.